Based on Stemirna's technology platform, the company has developed multiple therapeutic applications (tumor immunology, infectious diseases, etc.) and more than 20 product pipelines.
Highly differentiated pipeline aggregation in the field of infectious diseases and tumors
| Treatment Areas | Products In Research | Preclinical | Phase Ⅰ Clinical | Phase II Clinical | Phase III Clinical |
|---|---|---|---|---|---|
| infectious disease（precautionary） | |||||
| COVID-19 vaccine |
EUA
|
||||
| COVID-19 vaccine (Delta/Omicron B.A.2) |
IND Submitted
|
||||
| Rabies vaccine |
IND Enabling
|
||||
| Zoster vaccine |
IND Enabling
|
||||
| Flu vaccine |
IND Enabling
|
||||
| RSV vaccine |
IND Enabling
|
||||
| Monkeypox vaccine |
|
||||
| Malaria vaccine |
|
||||
| Tumor immunity（therapeutic） | |||||
| Personalized cancer vaccine (LPP-PCV) |
Clinical Phase I
|
||||
| IL-12 intratumoral injection |
|
||||
| HPV vaccine |
|
||||
| KRAS vaccine |
|
||||
| Tumor-Associated Antigens |
|
||||
| metabolic disease/rare disease（therapeutic） | |||||
| NAFLD |
|
||||
| phenylketonuria |
|
||||
沪公网安备 31011502015271号